33.22
price up icon5.39%   1.70
pre-market  プレマーケット:  33.24   0.02   +0.06%
loading
前日終値:
$31.52
開ける:
$30.9
24時間の取引高:
1.29M
Relative Volume:
1.82
時価総額:
$2.09B
収益:
-
当期純損益:
$-230.66M
株価収益率:
-7.9584
EPS:
-4.1742
ネットキャッシュフロー:
$-148.12M
1週間 パフォーマンス:
+1.13%
1か月 パフォーマンス:
-10.75%
6か月 パフォーマンス:
+52.04%
1年 パフォーマンス:
+114.46%
1日の値動き範囲:
Value
$29.81
$33.77
1週間の範囲:
Value
$29.81
$34.48
52週間の値動き範囲:
Value
$10.94
$47.84

Kodiak Sciences Inc Stock (KOD) Company Profile

Name
名前
Kodiak Sciences Inc
Name
セクター
Healthcare (1068)
Name
電話
650-281-0850
Name
住所
1250 PAGE MILL RD, PALO ALTO, CA
Name
職員
124
Name
Twitter
@kodiaksciences
Name
次回の収益日
2026-11-12
Name
最新のSEC提出書
Name
KOD's Discussions on Twitter

Compare KOD vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KOD icon
KOD
Kodiak Sciences Inc
33.22 2.09B 0 -230.66M -148.12M -4.1742
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.38 132.40B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.02 81.95B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
194.82 77.78B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
962.22 60.20B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
199.86 42.84B 742.00K -1.37B -1.07B -7.0731

Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-11 アップグレード H.C. Wainwright Neutral → Buy
2025-10-24 アップグレード JP Morgan Neutral → Overweight
2025-09-25 アップグレード Barclays Underweight → Equal Weight
2025-09-22 開始されました Jefferies Buy
2025-08-14 アップグレード JP Morgan Underweight → Neutral
2024-12-09 アップグレード Jefferies Hold → Buy
2024-09-05 開始されました H.C. Wainwright Neutral
2023-12-11 再開されました Goldman Sell
2023-11-17 アップグレード CapitalOne Equal Weight → Overweight
2023-07-27 ダウングレード UBS Buy → Neutral
2023-07-25 ダウングレード Chardan Capital Markets Buy → Neutral
2023-07-25 ダウングレード JP Morgan Neutral → Underweight
2023-07-24 ダウングレード CapitalOne Overweight → Equal Weight
2023-07-24 ダウングレード Jefferies Buy → Hold
2022-11-15 開始されました CapitalOne Overweight
2022-08-02 ダウングレード Citigroup Neutral → Sell
2022-02-24 ダウングレード JP Morgan Overweight → Neutral
2022-02-11 開始されました Goldman Buy
2022-02-02 アップグレード JP Morgan Neutral → Overweight
2021-05-11 アップグレード ROTH Capital Neutral → Buy
2021-03-12 開始されました Evercore ISI Outperform
2021-03-01 ダウングレード Barclays Equal Weight → Underweight
2021-02-17 ダウングレード ROTH Capital Buy → Neutral
2021-01-25 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-12-17 開始されました Berenberg Buy
2020-12-16 開始されました UBS Buy
2020-12-11 開始されました Citigroup Neutral
2020-11-30 ダウングレード JP Morgan Overweight → Neutral
2020-11-16 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-11-13 ダウングレード Goldman Buy → Neutral
2020-03-31 開始されました BMO Capital Markets Outperform
2020-03-03 開始されました Goldman Buy
2020-02-18 ダウングレード Barclays Overweight → Equal Weight
2020-02-06 開始されました SunTrust Buy
2020-01-08 開始されました ROTH Capital Buy
2020-01-03 開始されました Jefferies Buy
2019-12-24 開始されました JP Morgan Overweight
2019-10-15 繰り返されました Chardan Capital Markets Buy
2019-02-20 開始されました Chardan Capital Markets Buy
2018-10-29 開始されました Barclays Overweight
2018-10-29 開始されました BofA/Merrill Buy
2018-10-29 開始されました Morgan Stanley Overweight
すべてを表示

Kodiak Sciences Inc (KOD) 最新ニュース

pulisher
Sep 24, 2026

Kodiak Sciences Inc. (KOD) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026
pulisher
Sep 24, 2026

Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD) - finance.yahoo.com

Sep 24, 2026
pulisher
Sep 24, 2026

Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com

Sep 24, 2026
pulisher
Sep 24, 2026

Goldman Sachs Reinstates Coverage on Kodiak Sciences (KOD) with Neutral Rating Amid Sector Resilience - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run - finance.yahoo.com

Sep 24, 2026
pulisher
Sep 23, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research

Sep 23, 2026
pulisher
Sep 23, 2026

Kodiak Sciences stock faces a clinical catalyst this fall - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 22, 2026

4 Biotech Stocks With Key Clinical Readouts Expected This Fall - The Globe and Mail

Sep 22, 2026
pulisher
Sep 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com Nigeria

Sep 17, 2026
pulisher
Sep 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com

Sep 17, 2026
pulisher
Sep 16, 2026

Kodiak Sciences: DAYBREAK Needs To Deliver More Than A Passing Grade (NASDAQ:KOD) - Seeking Alpha

Sep 16, 2026
pulisher
Sep 13, 2026

3 Small-Cap Biotechs With Binary Catalysts on the Calendar - MarketBeat

Sep 13, 2026
pulisher
Sep 11, 2026

KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill

Sep 11, 2026
pulisher
Sep 03, 2026

Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance

Sep 03, 2026
pulisher
Sep 01, 2026

Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews

Sep 01, 2026
pulisher
Aug 27, 2026

Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com

Aug 27, 2026
pulisher
Aug 26, 2026

What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st

Aug 26, 2026
pulisher
Aug 21, 2026

Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria

Aug 20, 2026
pulisher
Aug 19, 2026

HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat

Aug 19, 2026
pulisher
Aug 18, 2026

GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat

Aug 18, 2026
pulisher
Aug 17, 2026

KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria

Aug 17, 2026
pulisher
Aug 17, 2026

HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo

Aug 17, 2026
pulisher
Aug 16, 2026

Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus

Aug 16, 2026
pulisher
Aug 15, 2026

California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat

Aug 15, 2026
pulisher
Aug 15, 2026

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat

Aug 14, 2026
pulisher
Aug 14, 2026

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail

Aug 14, 2026
pulisher
Aug 13, 2026

Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences Q2 net loss widens on higher R&D costs - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance

Aug 13, 2026
pulisher
Aug 12, 2026

Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK

Aug 12, 2026
pulisher
Aug 11, 2026

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC

Aug 11, 2026
pulisher
Aug 11, 2026

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView

Aug 11, 2026
pulisher
Aug 11, 2026

KOD Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Modest SupportRevenue Recognition Risk - vinanet.vn

Aug 11, 2026
pulisher
Aug 10, 2026

Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com

Aug 10, 2026
pulisher
Aug 10, 2026

Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang

Aug 10, 2026
pulisher
Aug 10, 2026

Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan

Aug 10, 2026
pulisher
Aug 10, 2026

Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView

Aug 10, 2026

Kodiak Sciences Inc (KOD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$58.29
price up icon 1.11%
$36.13
price down icon 1.87%
$121.55
price up icon 2.71%
$249.59
price up icon 1.25%
ONC ONC
$359.97
price down icon 1.38%
$199.86
price up icon 4.78%
大文字化:     |  ボリューム (24 時間):